Navigation Links
Sinovac Reports Unaudited Second Quarter Financial Results
Date:8/14/2014

100.0%

27,504

100.0%Cost of goods sold6,303

24.6%

6,853

24.9%Gross profit19,333

75.4%

20,651

75.1%Total sales for the first half of 2014 were $25.6 million, a decrease of 6.8% from $27.5 million in the same period of 2013. Sales for the first half of 2014 were impacted by decreased sales of the Company's hepatitis A vaccine, Healive, as a result of the challenging environment in the private-pay market.

Gross profit for the first half of 2014 was $19.3 million, a decrease of 6.4% from $20.7 million in the same period of 2013. Gross margin was 75.4% in the first half of 2014, compared to 75.1% in the same period of 2013.

Selling, general and administrative expenses for the first half of 2014 were $16.4 million, compared to $15.9 million for the same period of 2013.

R&D expenses in the first half of 2014 were $5.0 million, compared to $3.9 million in the same period of 2013. These expenses are primarily related to the continued advancement of pipeline vaccine candidates.Net loss attributable to stockholders in the first half of 2014 was $2.2 million or $(0.04) per basic and diluted share, compared to a net loss of $0.7 million, or $(0.01) per basic and diluted share, in the same period of 2013.

As of June 30, 2014, cash and cash equivalents totaled $89.6 million, compared to $107.2 million as of December 31, 2013. Net cash used in operating activities was $11.4 million during the first half of 2014. Net cash used in investing activities was $5.7 million, which was primarily used for payment
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results
2. Sinovac to Participate in UBS Asia Healthcare CEO Summit in November 2013
3. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
4. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
5. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
6. Pressure BioSciences, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update
7. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
8. Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
9. MarketResearch.com: New Biotechnology Market Research Reports Added to Kalorama Information Knowledge Center
10. GenVec Reports Second Quarter 2014 Financial Results
11. BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... ... managed with the use of special anti-vascular endothelial growth factor agents given by ... patients, currently does not have a scientific protocol for the many millions diagnosed ...
(Date:9/2/2015)... -- Biovista Inc. is glad to announce ... science challenge, a global competition hosted by the Rare ... the latest life science innovations and technologies. ... capability to support Steven Laffoon and his ... Niemann-Pick Disease Type A (NPA), a rare and fatal ...
(Date:9/2/2015)... ENGLEWOOD, Colo. , Sept. 2, 2015 ... focused on developing treatments for urological and related conditions, ... of its planned private placement convertible note financing, raising ... two prior tranches totaling $3.175 million. ... stated, "Proceeds from this private placement are intended to ...
(Date:9/2/2015)... 2, 2015 Biovista Inc. ... BeHEARD von 2015 bekanntgeben zu können. Hierbei handelt ... Institute. Biovista unterstützt mit seiner Möglichkeit ... Behandlung anderer Krankheiten als denen, für die ein ... und sein Team bei der Wylder Nation Foundation ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... DIEGO, Oct. 27 BioAtom Inc. (private) announced,today that ... Conference on,Tuesday, October 28, 2008 at 2:30 PM PDT ... San Diego, California., Myron Karasik, M.B.A., C.M.C., Director ... BioAtom Inc. of Costa Mesa, CA, dedicated,to development and ...
... 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ... on,endocrine therapy and oncology, today announced that it ... AEterna Zentaris that during the 30,consecutive business days ... of the,Company,s common shares had closed below the ...
... IDTA.PK) released today the Jant Pharmacal Corporation report,regarding ... markets., - The strategic partnership between Jant ... resulted in increasing market,penetration over the 2nd and ... significantly in the United States with over 100 ...
Cached Biology Technology:BioAtom Inc. To Present at BIOCOM Investor Conference 2008 2AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price 2AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price 3International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 2International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 3International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 4
(Date:8/11/2015)... , August 11, 2015 Today, ZUK announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a prominent smartphone manufacturer in ... selected FPC1 155 for ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the second ... Second quarter contract revenue of $ 85.2 million, ... margins of 26 % , Second quarter ... from royalties in the current quarter , Operating ... pleased to present another strong financial quarter, with all our divisions ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... produce many antibodies against the protein encapsulating the virus, most ... A new study suggests why some of the most common ... a form it takes after the virus has already invaded ... Hospital Boston and their colleagues. The findings, published ...
... People who contract gastroenteritis from drinking water contaminated with ... developing high blood pressure, kidney problems and heart disease in ... British Medical Journal . The findings underline the importance ... need for regular monitoring for those affected. It is ...
... SPRING HARBOR, N.Y. (Nov. 18, 2010) -- Sophisticated ... cells, tissues, and organ systems at extraordinary levels of ... However, finding the right imaging method and optimizing it ... for an established imaging laboratory. To fill this ...
Cached Biology News:Designing more effective anti-HIV antibodies 2Designing more effective anti-HIV antibodies 3E coli infection linked to long-term health problems 2First volume of new laboratory manual series on imaging is released 2
... Protein G bind specifically to Fc regions ... Protein G conjugates are commonly used as ... immunoglobulin subtypes from serum, hybridoma ascites fluids, ... These reagents are also commonly used to ...
... instrument engineered to match the speed of ... of research centers worldwide. It uses 1.5 ... ideally suited for high-speed temperature cycling due ... surface-area-to-volume ratio. ,By combining glass capillary tubes ...
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
... LNA microarray slides for microRNA expression ... incorporate Exiqons unique Locked Nucleic Acid (LNA) ... mismatch discrimination for short microRNA (miRNA) targets. ... 1 g total RNA (no need for ...
Biology Products: